What is the Hanall Biopharma Co. Ltd. stock price forecast?

Hanall Biopharma Co. Ltd. is currently trading at ₩57,000. View real-time AI analysis on Alpha Lenz.

What is Hanall Biopharma Co. Ltd. insider trading activity?

View the latest insider trading data for Hanall Biopharma Co. Ltd. on Alpha Lenz.

What is Hanall Biopharma Co. Ltd.'s P/E ratio?

Hanall Biopharma Co. Ltd.'s P/E ratio is -535.6.

Hanall Biopharma Co. Ltd.

KRX · 009420

₩57,000+6,100(+11.98%)Market closed

Ask about Hanall Biopharma Co. Ltd.'s future dividend policy...

Alpha Chat Insight

“Hanall Biopharma Co. Ltd. trades at a P/E of -535.6 (undervalued) with modest ROE of -3.4%. 3Y revenue CAGR of 12.2% highlights clear growth momentum.”

Ask for details →

Company Overview

Hanall Biopharma Co. Ltd. is a South Korean pharmaceutical company engaged in the research, development, production, and sale of biopharmaceutical products. Its primary function is to contribute to global health care through the creation of innovative drugs and therapies. Hanall Biopharma focuses on critical areas such as autoimmune diseases, ophthalmology, and oncology, striving to develop targeted solutions to meet unmet medical needs. The company is particularly noted for its biopharmaceutical and biosimilar products, which are significant in treating a range of serious conditions. In the financial market, Hanall Biopharma plays a critical role as an emerging player in the biopharma sector, recognized for its commitment to research and development and its collaborations with other international pharmaceutical firms. It has garnered attention for its strategic partnerships aimed at advancing novel treatments globally, thereby marking its presence in the global health landscape.

CEO정승원,박수진(공동대표이사)

Websitehttps://www.hanall.co.kr

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees304

Company Statistics

FY 2025

Profile

₩2,977,716,366,000Market Cap

₩155,184,524,100Revenue

52.24MShares Out

304Employees

Margins

52.10%Gross

1.83%EBITDA

-0.59%Operating

-3.98%Pre-Tax

-3.58%Net

Valuation

-535.64P/E

18.42P/B

19.19EV/Sales

1051.96EV/EBITDA

-180.95P/FCF

Growth (CAGR)

12.16%Rev 3Yr

11.86%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-2.54%ROA

-3.37%ROE

-2.76%ROIC

Financial Health

₩24,743,015,950Cash & Cash Equivalents

₩38,799,595,240Net Debt

39.30%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Hanall Biopharma Co. Ltd. trades at a P/E of -535.6 (undervalued) with modest ROE of -3.4%. 3Y revenue CAGR of 12.2% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Hanall Biopharma Co. Ltd. (ticker: 009420) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 304 employees. Market cap is $3.0T.

The current price is ₩57,000 with a P/E ratio of -535.64x and P/B of 18.42x.

ROE is -3.37% and operating margin is -0.59%. Annual revenue is $155.2B.